Amyotrophic Lateral Sclerosis Overview

Amyotrophic lateral sclerosis (ALS) is one of a group of disorders known as motor neuron diseases. It is characterized by the progressive degeneration and eventual death of nerve cells (motor neurons) in the brain and spinal cord that facilitate communication between the nervous system and voluntary muscles of the body. ALS affects both the upper and lower motor neurons, so that the transmission of messages is interrupted.

“Amyotrophic Lateral Sclerosis Pipeline Insight, 2022″ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Amyotrophic Lateral Sclerosis Market. 

The Amyotrophic Lateral Sclerosis Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details. 

Some of the key takeaways from the Amyotrophic Lateral Sclerosis Pipeline Report: 

• Companies across the globe are diligently working toward developing novel Amyotrophic Lateral Sclerosis treatment therapies with a considerable amount of success over the years. Amyotrophic Lateral Sclerosis Key players such as – Acurastem, Everfront Biotech Co., Ltd, Eledon Pharmaceuticals, AL-S Pharma, Novartis, Annexon Biosceinces, MediciNova, Treeway, Biogen, and others, are developing therapies for the Amyotrophic Lateral Sclerosis treatment 

• Amyotrophic Lateral Sclerosis Emerging therapies such as – AS-202, HK001, Tegoprubart, AP-101, BLZ945, ANX005, MN-166, TW001, BIIB067, and others are expected to have a significant impact on the Amyotrophic Lateral Sclerosis market in the coming years. 
• On 29 August 2016, orphan designation (EU/3/16/1732) was granted by the European Commission to Biogen Idec Limited,United Kingdom, for synthetic ribonucleic acid oligonucleotide directed against superoxide dismutase 1 messenger ribonucleic acid (also known as BIIB067) for the treatment of amyotrophic lateral sclerosis   
• In October 2021, Biogen Inc. announced topline results from its pivotal Phase 3 VALOR study of tofersen (BIIB067), an investigational antisense drug being evaluated for people with superoxide dismutase 1 (SOD1) amyotrophic lateral sclerosis (ALS)

Amyotrophic Lateral Sclerosis Pipeline Therapeutics Assessment

• Amyotrophic Lateral Sclerosis Assessment by Product Type
• Amyotrophic Lateral Sclerosis By Stage and Product Type
• Amyotrophic Lateral Sclerosis Assessment by Route of Administration
• Amyotrophic Lateral Sclerosis By Stage and Route of Administration
• Amyotrophic Lateral Sclerosis Assessment by Molecule Type
• Amyotrophic Lateral Sclerosis by Stage and Molecule Type 

DelveInsight’s Amyotrophic Lateral Sclerosis Report covers around 100+ products under different phases of clinical development like

• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration 

Emerging Amyotrophic Lateral Sclerosis Drugs Under Different Phases of Clinical Development Include: 

• AS-202: Acurastem
• HK001: Everfront Biotech Co., Ltd
• Tegoprubart: Eledon Pharmaceuticals
• AP-101: AL-S Pharma
• BLZ945: Novartis
• ANX005: Annexon Biosceinces
• MN-166: MediciNova
• TW001: Treeway
• BIIB067: Biogen 

Get a Free Sample PDF Report to know more about Amyotrophic Lateral Sclerosis Pipeline Assessment- https://www.delveinsight.com/sample-request/amyotrophic-lateral-sclerosis-als-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr

Amyotrophic Lateral Sclerosis Pipeline Analysis:

The Amyotrophic Lateral Sclerosis pipeline report provides insights into 

• The report provides detailed insights about companies that are developing therapies for the Amyotrophic Lateral Sclerosis treatment with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Amyotrophic Lateral Sclerosis Treatment.
• Amyotrophic Lateral Sclerosis key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Amyotrophic Lateral Sclerosis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Amyotrophic Lateral Sclerosis market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Further Amyotrophic Lateral Sclerosis product details are provided in the report. Download the Amyotrophic Lateral Sclerosis pipeline report to learn more about the emerging Amyotrophic Lateral Sclerosis therapies

Amyotrophic Lateral Sclerosis Pipeline Market Drivers

• Rising incidence of Amyotrophic Lateral Sclerosis
• Increasing geriatric population
• Improving Healthcare Infrastructure
• Demand for New and Effective Drugs

Amyotrophic Lateral Sclerosis Pipeline Market Barriers

• Aggressive nature of disease and the complexity of targeting the CNS
• The current standard of care for patients with newly-diagnosed Amyotrophic Lateral Sclerosis has limited effectiveness and a second line has not been established

Scope of Amyotrophic Lateral Sclerosis Pipeline Drug Insight    

• Coverage: Global
• Key Amyotrophic Lateral Sclerosis Companies: Acurastem, Everfront Biotech Co., Ltd, Eledon Pharmaceuticals, AL-S Pharma, Novartis, Annexon Biosceinces, MediciNova, Treeway, Biogen, and others
• Key Amyotrophic Lateral Sclerosis Therapies: AS-202, HK001, Tegoprubart, AP-101, BLZ945, ANX005, MN-166, TW001, BIIB067, and others
• Amyotrophic Lateral Sclerosis Therapeutic Assessment: Amyotrophic Lateral Sclerosis current marketed and Amyotrophic Lateral Sclerosis emerging therapies
• Amyotrophic Lateral Sclerosis Market Dynamics:  Amyotrophic Lateral Sclerosis market drivers and Amyotrophic Lateral Sclerosis market barriers 

Request for Sample PDF Report for Amyotrophic Lateral Sclerosis Pipeline Assessment and clinical trials

Table of Contents

Download Sample PDF Report to know more about Amyotrophic Lateral Sclerosis drugs and therapies

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: Send Email
Phone: +91 9568243403
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com